Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease

Autor: Marko Aleksic, Sanja Stankovic, Stanimir Kiurski, Milica Stojkovic Lalosevic, Jovan Lalosevic, Ivana Jovicic, Mihailo Stjepanovic, Stefan Stojkovic, Aleksandra Pavlovic Markovic, Djordje Culafic, Milos Stulic, Mirjana Stojkovic, Branislav Oluic, Tamara Milovanovic, Sanja Dragasevic, Ljubisa Toncev, Marija Stojanović
Rok vydání: 2020
Předmět:
Male
Medicine (General)
Clinical Biochemistry
Inflammatory bowel disease
Gastroenterology
0302 clinical medicine
hemic and lymphatic diseases
030212 general & internal medicine
Anemia
Iron-Deficiency
biology
medicine.diagnostic_test
Complete blood count
General Medicine
Middle Aged
3. Good health
Serum iron
Female
030211 gastroenterology & hepatology
medicine.symptom
Research Article
Anemia of chronic disease
inorganic chemicals
Adult
congenital
hereditary
and neonatal diseases and abnormalities
medicine.medical_specialty
Article Subject
Inflammation
digestive system
03 medical and health sciences
R5-920
Hepcidins
Hepcidin
Internal medicine
Genetics
medicine
Humans
Molecular Biology
Soluble transferrin receptor
business.industry
Biochemistry (medical)
nutritional and metabolic diseases
Inflammatory Bowel Diseases
medicine.disease
Blood Cell Count
Iron-deficiency anemia
Case-Control Studies
Ferritins
biology.protein
business
Biomarkers
Zdroj: Disease Markers, Vol 2020 (2020)
Disease Markers
ISSN: 1875-8630
0278-0240
Popis: Background and Aim. Differentiating iron deficiency anemia (IDA) from anemia of chronic disease (ACD) in patients with inflammatory bowel disease (IBD) represents a clinical challenge. Hepcidin is a polypeptide synthetized in the liver, and iron levels or inflammation mostly regulate hepcidin production. Our aim was to determine serum hepcidin levels in patients with inflammatory bowel disease (IBD) as well to investigate whether hepcidin levels correlate with disease activity. Material and Methods. A case-control study was preformed among newly diagnosed IBD patients and same number age- and sex-matched healthy controls. All patients underwent a total ileocolonoscopy. Complete blood count was obtained in addition to inflammatory markers (CRP, erythrocyte sedimentation rate-ESR). Serum levels of hepcidin were determined with commercially available enzyme-linked immunosorbent assay (DRG Instruments Marburg, Germany). Serum iron, TIBC, and UIBC were assessed with an electrochemiluminesence immunoassay, and soluble transferrin receptor (sTfR) was assessed using an immunoturbidimetric method. Mayo score and CDAI, respectively, were calculated for each patient. Statistical analyses were performed using the SPSS software version 20.0 for Windows. Results. There was a high statistically significant difference between IBD patients and controls in levels of hepcidin ( P < 0.01 ). Namely, serum hepcidin levels were significantly higher in the control group. There was no statistically significant correlation of serum hepcidin with CRP, Mayo score, or CDAI, respectively ( P > 0.05 ). However, we have found a statistically significant negative correlation of sTfR and TIBC with hepcidin ( P < 0.01 ). Conclusion. Results of our study suggest that hepcidin is a reliable marker of IDA in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje